In this episode we sit down with Adam Foresman, co-founder and CEO of Ryden.ai, a groundbreaking startup that’s redefining how MedTech companies approach compliance.

After nearly two decades in quality and regulatory leadership—including roles at Dentsply, Midmark, and Vidya Health—Adam saw firsthand how overwhelming it had become to stay audit-ready across constantly shifting global regulations. So he built the tool he wished he had.

Ryden.ai leverages AI to continuously scan a company’s QMS, identify compliance gaps, and recommend updates based on global regulatory standards (FDA, ISO, EUMDR, Health Canada, and more). And it doesn’t stop there—it’s expanding to assess records, not just procedures, ensuring companies can demonstrate execution, not just intention.

In this conversation, Adam shares:

Why AI won’t replace quality pros—but will make their jobs a lot easier

The biggest concerns companies have about using AI in GxP environments (and how Ryden addresses them)

What the FDA’s own shift to AI tools means for regulatory strategy

How both startups and enterprise MedTech teams are using Ryden to stay ahead

A real-world win preparing a company for Health Canada with zero major findings

Whether you're a startup with limited resources or an enterprise with global sites to manage, Adam makes a compelling case: AI won’t take your job—but it might save your sanity.

Adam Foresman on LinkedIn: https://www.linkedin.com/in/adamforesman/

Ryden.ai on the web: ryden.ai